Low-Dose Subcutaneous Alemtuzumab in Refractory Chronic Lymphocytic Leukaemia (CLL): Results of a Prospective, Single-Arm Multicentre Study

Leukemia - United Kingdom
doi 10.1038/leu.2009.148
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)

Current Hematologic Malignancy Reports
Cancer ResearchOncologyHematology
2016English

The Use of Low-Dose Alemtuzumab in Pretreated B-Cell Chronic Lymphocytic Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2010English

Cost-Effectiveness of Ibrutinib in Patients With Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL) in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Filgrastim and Alemtuzumab (Campath-1h) for Refractory Chronic Lymphocytic Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2005English

Relationship Between Comorbidities at Diagnosis, Survival and Ultimate Cause of Death in Patients With Chronic Lymphocytic Leukaemia (CLL): A Prospective Cohort Study

British Journal of Haematology
Hematology
2017English

Analysis of Treatment Options for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Chronic Lymphocytic Leukaemia

Nature Reviews Disease Primers
Medicine
2017English

A Phase II Trial of Eltrombopag for Patients With Chronic Lymphocytic Leukaemia (CLL) and Thrombocytopenia

British Journal of Haematology
Hematology
2018English

Comparative Analysis of Targeted Novel Therapies in Relapsed, Refractory Chronic Lymphocytic Leukaemia

Haematologica
Hematology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy